arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Entera Bio Ltd.

ENTX Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$2.87
▼ -5.9% Today
as of Oct 23, 13:02 ET
Last 30 days +1.77% Sep 14 → Oct 23
$2.45 $2.61 $2.77 $2.93 $3.09 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$3.01
High
$3.04
Low
$2.92
Volume
$629,441
Avg Vol
$845,936
Mkt Cap
$503M
P/E (TTM)
9.57
Beta
—
52w High
$4.20
52w Low
$0.91
Div Yield
—
Shares Out
$49M

Recent Press Releases & News last 60 days · 6 items

Oct 13 · 11:00 PR GlobeNewswire
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
Oct 8 · 12:00 PR GlobeNewswire
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
Oct 6 · 12:00 PR GlobeNewswire
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
▸ Show all 6 press releases & news Free account →

ENTX earnings at a glance

The options market is pricing a move of about ±14.2% after the report, a range of roughly $2.46 to $3.28 from today's $2.87. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±4.1% on average; after the most recent report on May 8, 2026 it moved -5.1%. That means options currently expect more movement than ENTX has typically delivered. ENTX beat the consensus EPS estimate in 3 of its last 3 reported quarters. Implied volatility is currently 71%. The share price of $2.87 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$0.91
$4.20
60% of range
Avg surprise (last 3)
+16.3%
Avg reaction (last 2)
-4.1%
0% positive
Latest IV / EM
71%
EM ±14.2% · $3 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.09$-0.03$0.03$0.08$0.14 Actual $0.08Actual $0.08Actual $0.08Actual $0.05Actual $0.06Actual $0.08Actual $-0.06Est $-0.07Actual $-0.06Actual $-0.07Est $-0.09Actual $-0.07Est $-0.08Actual $0.14 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-7M$-5M$-4M$-2M$44,100 Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $0.14 — — — — financials
Fri May 8, 2026Mar/2026 $-0.07 $-0.08 +12.5% -16.7% -5.1% earnings
Fri Nov 14, 2025Sep/2025 $-0.07 $-0.09 +22.2% — — earnings
Fri Aug 8, 2025Jun/2025 $-0.06 — — — — earnings
Fri May 9, 2025Mar/2025 $-0.06 $-0.07 +14.3% — -3.2% earnings
Mon Sep 30, 2024Sep 2024 $0.08 — — — — financials
Sun Jun 30, 2024Jun 2024 $0.06 — — — — financials
Sun Mar 31, 2024Mar 2024 $0.05 — — — — financials
Sat Sep 30, 2023Sep 2023 $0.08 — — — — financials
Fri Jun 30, 2023Jun 2023 $0.08 — — — — financials
Fri Mar 31, 2023Mar 2023 $0.08 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$0$0—$0$0$42,000—$42,000
Cost of revenue$0$0—$0$0$42,000—$42,000
Gross profit$0$0—$0$0$0—$0
Operating income$-5M$-4M—$-3M$-3M$-3M—$-3M
Net income$-7M$-4M—$-3M$-3M$-3M—$-3M
EPS (diluted)$0.14$0.07—$0.07$0.06$0.06—$0.08

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$11M$4M$7M$9M$11M$13M$9M$7M
Inventory————————
Total current assets$19M$12M$15M$17M$19M$21M$9M$7M
Total assets$19M$13M$16M$17M$20M$22M$9M$8M
Long-term debt————————
Total liabilities$12M$2M$3M$2M$2M$2M$1M$1M
Total equity$7M$11M$13M$15M$17M$19M$8M$6M

Implied volatility — last 90 days

39%733%1427%2121%2816% Jun 07 — IV 214% · EM ±29.7%Jun 08 — IV 210% · EM ±27.8%Jun 09 — IV 1734% · EM ±217.2%Jun 10 — IV 543% · EM ±64.1%Jun 11 — IV 780% · EM ±86.2%Jun 26 — IV 64% · EM ±12.3%Jun 29 — IV 71% · EM ±12.6%Jul 01 — IV 106% · EM ±17.8%Jul 08 — IV 1440% · EM ±180.5%Jul 10 — IV 1695% · EM ±187.3%Jul 14 — IV 2816% · EM ±203.7%Jul 21 — IV 110% · EM ±25.5%Jul 22 — IV 565% · EM ±129.3%Jul 23 — IV 428% · EM ±96.2%Jul 24 — IV 839% · EM ±185.4%Jul 27 — IV 160% · EM ±33.5%Jul 28 — IV 186% · EM ±38.0%Jul 29 — IV 156% · EM ±31.2%Jul 30 — IV 138% · EM ±26.9%Jul 31 — IV 45% · EM ±8.6%Aug 03 — IV 205% · EM ±36.3%Aug 04 — IV 147% · EM ±25.3%Aug 05 — IV 144% · EM ±24.0%Aug 10 — IV 475% · EM ±65.8%Aug 11 — IV 265% · EM ±35.0%Aug 12 — IV 448% · EM ±56.2%Aug 18 — IV 548% · EM ±39.7%Aug 19 — IV 688% · EM ±40.6%Aug 20 — IV 1078% · EM ±45.0%Aug 26 — IV 39% · EM ±7.8%Aug 27 — IV 50% · EM ±9.8%Aug 28 — IV 43% · EM ±8.3%Aug 31 — IV 67% · EM ±11.9%Sep 01 — IV 80% · EM ±13.8%Sep 02 — IV 92% · EM ±15.4%Sep 03 — IV 63% · EM ±10.2%Sep 09 — IV 98% · EM ±12.3%Sep 10 — IV 152% · EM ±17.9%Sep 11 — IV 159% · EM ±17.6%Sep 14 — IV 170% · EM ±14.2%Sep 15 — IV 193% · EM ±14.0%Sep 23 — IV 71% · EM ±14.2%

Sector peers

RGNX
REGENXBIO Inc.
$501M $6.79-5.3%
ALLO
Allogene Therapeutics, Inc.
$494M $1.22-8.3%
AUTL
Autolus Therapeutics plc
$492M $1.52-6.2%
PROK
ProKidney Corp.
$517M $1.39-3.5%
TECX
Tectonic Therapeutic, Inc.
$444M $20.44-6.4%
EIKN
Eikon Therapeutics, Inc.
$564M $7.47-6.6%

ENTX earnings FAQ

What is ENTX's expected move for earnings?

Options currently price a move of about ±14.2%, or $0.41 per share either way from $2.87.

How does ENTX stock usually react to earnings?

Across the last 2 reports the average next-day move was ±4.1%, up 0 times and down 2 times.

What is ENTX's implied volatility?

ENTX's at-the-money implied volatility is about 71% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in